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Abstract
1. Laromustine (VNP40101M, also known as Cloretazine) is a novel sulfonylhydrazine 
alkylating (anticancer) agent. This article describes the use of quantitative whole-body 
autoradiography (QWBA) and mass balance to study the tissue distribution, the excretion 
mass balance and pharmacokinetics after intravenous administration of 
[14C]VNP40101M to rats. A single 10 mg/kg IV bolus dose of [14C]VNP40101M was 
given to rats.
2. The recovery of radioactivity from the Group 1 animals over a 7-day period was an 
average of 92.1% of the administered dose, which was accounted for in the excreta and 
carcass. Most of the radioactivity was eliminated within 48 h via urine (48%), with less 
excreted in feces (5%) and expired air accounted for (11%). The plasma half-life of 
[14C]laromustine was approximately 62 min and the peak plasma concentration (Cmax) 
averaged 8.3 μg/mL
3. The QWBA study indicated that the drug-derived radioactivity was widely distributed to 
tissues through 7 days post-dose after a single 10 mg/kg IV bolus dose of 
[14C]VNP40101M to male pigmented Long–Evans rats. The maximum concentrations 
were observed at 0.5 or 1 h post-dose for majority tissues (28 of 42). The highest 
concentrations of radioactivity were found in the small intestine contents at 0.5 h 
(112.137 μg equiv/g), urinary bladder contents at 3 h (89.636 μg equiv/g) and probably 
reflect excretion of drug and metabolites. The highest concentrations in specific organs 
were found in the renal cortex at 1 h (28.582 μg equiv/g), small intestine at 3 h (16.946 
μg equiv/g), Harderian gland at 3 h (12.332 μg equiv/g) and pancreas at 3 h (12.635 μg 
equiv/g). Concentrations in the cerebrum (1.978 μg equiv/g), cerebellum (2.109 μg 
equiv/g), medulla (1.797 μg equiv/g) and spinal cord (1.510 μg equiv/g) were maximal at 
0.5 h post-dose and persisted for 7 days.
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4. The predicted total body and target organ exposures for humans given a single 100μCi IV 
dose of [14C]VNP40101M were well within the medical guidelines for maximum 
radioactivity exposures in human subjects.
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Introduction
Laromustine [VNP40101M, 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-
(methylamino)carbonylhydrazine] is an active member of a relatively new class of 
sulfonylhydrazine prodrugs under development as antineoplastic alkylating agents 
(Baumann et al., 2005; Penketh et al., 2004). The chemical structure of laromustine is shown 
in Figure 1. Laromustine generates two distinct types of reactive intermediates: 90CE and 
methylisocyanate. 90CE and other hard chloroethylating (DNA-reactive) species alkylate 
DNA at the O6-position of guanine residues that progress to G-C interstrand cross-links 
(Penketh et al., 2000, 2004). Methylisocyanate, a soft electrophilic carbamoylating agent, 
binds preferentially and stoichiometrically to sulfhydryl groups and inhibits a number of 
enzymes, including O6-alkylguanine-DNA-alkyltransferase (AGT), a DNA repair enzyme. 
The release of methylisocyanate and its inhibition of DNA repair by AGT is thought to 
augment the antineoplastic effect of 90CE and related chloroethylating species. This process 
probably accounts for the considerably greater antineoplastic activity of laromustine relative 
to that of other sulfonylhydrazine alkylating agents, many of which generate 90CE like 
laromustine, but in contrast to laromustine do not generate methylisocyanate (Baumann et 
al., 2005). Laromustine displays anticancer activity against a broad spectrum of transplanted 
tumors (Finch et al., 2001) and exhibited antileukemic activity in initial clinical trials (Giles 
et al., 2004).
Mass balance studies using radiolabeling can facilitate the quantification of the drug and 
drug-related substances in blood, plasma, urine and feces collected from the study subjects. 
Information about the total fate of drug-related material and routes of excretion can be 
obtained from mass balance studies (Park et al., 1997; Schadt et al., 2012). QWBA studies 
provide the tissue distribution and pharmacokinetics data required for new drug registration 
and for predicting human exposure to radioactivity during clinical radiolabeled mass balance 
studies (Gifford et al., 2008; Wang et al., 2011). Both QWBA and mass balance studies are 
required for regulatory filings of a new drug entity and for projecting tissue dosimetry in 
human mass balance studies (Scicinski et al., 2012).
Recently, we reported an in vitro evaluation of the victim and perpetrator potential of the 
anti-cancer agent laromustine (Nassar et al., 2009). In addition, the in vitro metabolite 
profiling and mass balance of [14C]VNP40101M in rat, dog, monkey and human liver 
microsomes was reported (Nassar et al., 2010a,b,c). The in vitro studies found that 
VNP40101M and VNP4090CE undergo activation in human liver microsomes. Phase 1 
metabolism of laromustine was reported recently and showed that laromustine undergoes 
rearrangement, dehalogenation and hydrolysis at physiological pH to form active moieties 
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(Nassar et al., 2010a,b,c, 2011). This article describes the investigation of tissue sections and 
mass balance of rats after a single 10 mg/kg IV bolus dose of [14C]VNP40101M.
Materials and methods
[14C]Laromustine (labeled in the ethane side chain, see Figure 1, asterisks indicate site 
of 14C-label). The radiolabeled test article was stored in a −20 °C freezer protected from 
light, and the non-radiolabeled material was stored at 2–8 °C. As determined by Moravek 
Biochemicals, Inc. (Brea, CA), the specific activity was 57.3 mCi/mmol. Prior to use, the 
radiochemical purity of [14C]VNP40101M was confirmed using an HPLC method. All 
chemicals and reagents used were analytical grade, and the chromatographic solvents used 
were HPLC grade. Some of the equipment used for this study included liquid scintillation 
counter (Packard Bioscience Company model TR-2900), sample oxidizer (Packard 
Bioscience Company model 307) and stomacher circulator (Seward model 400).
Mass balance
Dose administration
This study was performed using a total of 12 male Sprague–Dawley rats (not including 
replacement animals and blood donors): 4 assigned to Group 1 (excretion mass balance), 4 
assigned to Group 2 (expired air collection) and 4 assigned to Group 3 (pharmacokinetics). 
Animals were not fasted overnight prior to [14C]VNP40101M dose administration. The 
volume of the dose solution administered to each rat was determined based upon the pre-
dose body weight of each animal obtained the morning of dosing. Each animal in Group 1, 2 
and 3 received a single intravenous bolus dose of [14C]VNP40101M at a target dose of 10 
mg/kg. The IV dose volume was 2 mL/kg. The dose was administered through a femoral 
vein cannula. The dose contained a combination of non-radiolabeled VNP40101M and 
[14C]VNP40101M to achieve the target doses as shown below.
Study groups and target doses.
Group
number
No./sex
of
animals
Dose
route
Target
dose
concentration
(mg/mL)
Target
dose
volume
(mL/kg)
Target
dose
(mg/kg)
Target
radioactivity
dose
(μCi/kg)
1 (FVC) 4/M IV 5 2 10 100
2 (FVC) 4/M IV 5 2 10 100
3 (FVC/JVC) 4/M IV 5 2 10 100
Test animals
Male Sprague–Dawley rats used in this study were 7 weeks old on day of dosing and were 
obtained from Hilltop Laboratories (Scottdale, PA). Animals were acclimated in the test 
facility at least 2 days before study initiation. Before being placed in the study, each animal 
was weighed, assigned a permanent identification number, and identified with a tail mark. 
All the animals were not fasted and weighed between 255 and 344 g at the time of dosing.
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Formulations
Dosing formulations were freshly prepared on the day of dosing and assayed for 
radioactivity concentration on each day of dosing. The IV dosing formulation was prepared 
by diluting a stock solution containing 10 mg/mL VNP40101M in 30% ethyl alcohol, 70% 
polyethylene glycol 300, 6 mg/mL citric acid, with [14C]VNP40101M and 5% dextrose in 
water (D5W). The administered formulation thus contained 5 mg/mL VNP40101M, 15% 
ethanol and 35% polyethylene glycol 300 in D5W. The solution was vortexed to achieve 
homogeneity. The dose solution was stirred continuously using a magnetic stirrer throughout 
the dose administration procedure.
Sample collections
Animals study design and dosing regimen
Group 1: Feces, urine, cage rinses, cage washes, cage wipes and carcasses: Group 1 rats 
were housed in plastic (Nalgene®) metabolism cages. Urine samples were collected into 
labeled polypropylene containers maintained on dry ice at pre-dose and at post-dose 
intervals of 0–4, 4–8, 8–24 and at 24 h intervals up to 168 h. Feces samples were collected 
into labeled polypropylene containers maintained on dry ice at pre-dose, 0–24 h and at 24 h 
post-dose intervals up to 168 h. A post-dose cage rinse was performed for each metabolism 
cage at each 24 h interval after urine and feces collections, up to 144 h post-dose. Cage 
rinses were performed with approximately 30 mL of a mixture of reagent alcohol/ deionized 
water (50:50). After the last excreta collection at 168 h post-dose, each cage was washed 
with approximately 90 mL of RadiacWash (100%) and wiped down with gauze pads (cage 
wipe). At 168 h post-dose, the body weight of each animal was measured and then each 
animal was euthanized in a CO2 chamber. Each carcass was stored in a labeled plastic bag 
and retained for radioanalysis. The weight of each sample (i.e. urine, feces, cage residues 
and carcasses) was recorded in the study records.
Group 2: expired air: Group 2 rats were housed in glass metabolism cages required for the 
collection of expired air. The circulating air exiting the cage was passed through absorption 
columns where the expired 14CO2 gas was trapped in a solution of Carbo-Sorb®. The 14CO2 
scrubber liquids were collected from the system during pre-dose, 0–24 and 24–48 h post-
dose.
Group 3: blood for plasma pharmacokinetics: Group 3 rats were housed in plastic 
metabolism cages. Blood samples were collected from Group 3 animals for characterizing 
the pharmacokinetics of plasma radioactivity. The blood samples were collected at pre-dose, 
0.083, 0.25, 0.50, 1, 2, 4, 7, 10, 24 and 48 h post-dose. The blood samples for each rat (~0.8 
mL) were collected from the jugular vein cannula into tubes containing sodium heparin as 
an anticoagulant and 0.02 mL of 2 M citric acid as a stabilizing agent. Samples were 
centrifuged within 1h of collection at 3000 rpm for 10 min at 4°C and plasma was harvested, 
snap frozen and stored at − 70 °C. After blood withdrawal, approximately 0.8 mL of fresh 
blood from a donor rat was transfused back into each rat. Blood donor animals were healthy 
naive Sprague–Dawley rats.
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Sample preparation and radioanalytical methods
All samples directly counted by LSC (plasma, urine, cage rinse, cage wash, extracts of cage 
wipes and solubilized carcasses) were analyzed using Ultima Gold scintillation cocktail 
(Packard, Groningen, The Netherlands). All samples were counted using a Model 2900TR 
liquid scintillation analyzer (Packard, Groningen, The Netherlands) and counting was for at 
least 5 min or 100 000 counts. The LSC data in counts per minute (cpm) were automatically 
corrected for counting efficiency using an external standard and an instrument-stored quench 
curve generated from sealed quenched standards to obtain disintegrations per minutes 
(dpm). The LSC data were corrected for background by subtracting the dpm value measured 
from the analysis of a blank sample. Dosing solution aliquots and feces homogenates were 
analyzed in triplicate. Urine, plasma, expired air and cage residues (i.e. rinse, wash and 
wipe) were analyzed in duplicate. If results for duplicate samples (calculated as 14C dpm/g 
sample) differed by more than 10% from the mean value, the sample was re-homogenized 
(where appropriate) and reanalyzed. If results for triplicate sample replicates had a %CV 
greater than 10%, the sample was re-homogenized (where appropriate) and reanalyzed. This 
specification was met for all sample aliquots that had radioactivity greater than 500 dpm.
Analysis of urine (Group 1)
Prior to analysis and immediately after removal from the storage freezer, 2 M citric acid at a 
volume of 2.5% of the sample weight was added to each urine specimen, and then the 
specimens were thawed. Each sample was brought to room temperature, mixed thoroughly 
and duplicate aliquots (target 0.5 mL) were transferred to labeled scintillation vials. After 
adding 10 mL of Ultima Gold scintillation cocktail to each sample and mixing, the samples 
were analyzed for radioactivity.
Analysis of feces (Group 1)
Feces samples were thawed and brought to room temperature, mixed with 0.1 M citric acid 
(ca. 2–3 times the feces weight and enough to create a slurry), and the total homogenate 
weight was recorded. All the samples were homogenized using a Stomacher 400 Circulator. 
Triplicate weighed aliquots (ca. 0.5 g) of each homogenate were added to Combusto Cones® 
with Combusto Pads® and placed in labeled scintillation vials. Fecal samples were 
combusted in a Model 307 Sample Oxidizer (Packard Instrument Co., Downers Grove, IL) 
and the resulting 14CO2 was trapped in CarboSorb. Perma-Fluor scintillation cocktail 
(Packard) was added and the radioactivity content quantitated by LSC.
Analysis of cage wash, cage rinse and cage wipe specimens (Group 1)
Cage wash and cage rinse samples were thawed, brought to room temperature. Duplicate 
aliquots (0.5 mL) of cage wash and cage rinse samples were transferred to labeled 
scintillation vials and Ultima Gold scintillation cocktail (10 mL) was added. Samples were 
then analyzed for radioactivity.
Cage wipes from each cage were thawed, transferred to a labeled polypropylene container 
and soaked overnight at room temperature in 50% methanol:50% distilled water to extract 
[14C]-radioactivity. Duplicate sample aliquots (0.5 mL) were transferred to labeled 
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scintillation vials and Ultima Gold scintillation cocktail (10 mL) was added. Samples were 
then analyzed for radioactivity.
Analysis of carcasses (Group 1)
Carcasses were solubilized in 6N KOH by stirring at room temperature until particulate 
matter was no longer present. Once homogenized, triplicate weighed aliquots (ca. 0.5 g 
each) were removed, bleached using hydrogen peroxide and analyzed for radioactivity.
Analysis of expired air (Group 2)
The Carbo-Sorb® trapping solution (expired air samples) was allowed to approach room 
temperature, mixed thoroughly and duplicate aliquots (0.5 mL) of individual samples were 
transferred to labeled scintillation vials. Hionic Fluor scintillation cocktail (10 mL) was 
added and samples were then analyzed for radioactivity using LSC.
Analysis of plasma samples (Group 3)
Plasma samples were thawed and brought to room temperature, mixed thoroughly and 
duplicate aliquots (0.05 mL) were transferred to labeled scintillation vials. Ultima Gold 
scintillation cocktail (10 mL) was added, and the samples were mixed and analyzed for 
radioactivity.
Calculations used for sample analysis
Samples not homogenized:
Sample dpm/g (or/mL) = Sample aliquot dpm/Sample aliquot weight (or volume)
Samples homogenized:
Homogenate dpm/g (or/mL) = Homogenate aliquot dpm/Homogenate aliquot weight (or 
volume)
Sample total dpm = Homogenate dpm/g (or/mL) × Total homogenate weight (or 
volume)
Sample dpm/g (or/mL) = Sample total dpm/S ample total weight (or volume)
All samples
LSC LLOQ = 2 × cpm of background vial with background subtraction (any value 
lower than LLOQ were set to zero for calculation)
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Total μCi in sample = Mean μCi/g(or/mL) × Total sample weight
Data analysis
The following criteria were used to determine the acceptance or re-analysis of liquid 
scintillation counting (LSC) results: excluding plasma samples, if the LSC results for 
duplicate samples (calculated as dpm/g sample) differed by more than 10% from the mean 
value, the remaining sample was re-aliquoted and reanalyzed. The initial LSC results for 
duplicate plasma aliquots were reported as determined since there was insufficient volume 
for sample reanalysis. If LSC results for triplicate samples had a CV >10% and an average 
radioactivity greater than 500 dpm, the remaining sample was re-homogenized and 
reanalyzed. Data tables were compiled with the mean and standard deviation calculated 
using Excel. The data presented in the summary tables reflect the data recorded in the study 
records and the data presented in the report text have been rounded appropriately to 
summarize results. Non-compartmental pharmacokinetic parameters were calculated for 
plasma concentrations using WinNonlin™ (Pharsight Corporation, Sunnyvale, CA). The λz 
was obtained, where possible, by linear regression of the terminal elimination phase of a 
log-linear plot of plasma concentration-time data. The observed maximum plasma 
concentration (Cmax) was determined directly from the concentration-time profile. The area 
under the plasma concentration-time curve from time 0 to the last quantifiable plasma 
concentration (AUC0–t; AUC0–t was equivalent to AUC0–48 h in this study) and the area 
under the plasma concentration-time curve from time 0 to infinity [AUC(0–∞)] were 
determined by the linear trapezoidal rule.
Whole-body autoradiography
Dose solution and analysis
Prior to dosing, the concentration and homogeneity of each formulation were checked using 
LSC. Triplicate pre-dose and post-dose aliquots (0.1 mL from each of top, middle and 
bottom of vial) of the dose solution were taken and diluted to 10 mL with ethanol. Aliquots 
of the diluted dose solutions were analyzed for 10 min by LSC. The mean pre-dose 
radioactivity concentration was used in calculating the amount of radioactivity administered 
to each animal. The mean concentration of radioactivity was 38.1 μCi/g (pre-dose assay). 
The radiochemical purity of [14C]VNP40101M in the dosing formulation was examined by 
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radio-HPLC in both pre-dose and post-dose aliquots. The stability of [14C]VNP40101M in 
the dose solution was determined by analyzing pre-dose and post-dose aliquots by the radio-
HPLC method, and the test article was considered to be stable under the conditions of dose 
formulation preparation and through the completion of dose administration.
Animal experimentation
Eleven male pigmented Long–Evans rats, approximately 8 weeks old, with a body weight 
range of 240.2–278.1 g, with cannulated femoral veins, were used for this study. The Long-
Evans rats were supplied by Hilltop Lab Animals, Inc. (Scottdale, PA). All the rats were 
maintained on Certified Rodent Diet® #5002 (PMI Nutrition International, Richmond, IN), 
and filtered water from domestic supply (Artesian Water, Inc., Newark, DE) provided ad 
libitum. The rats were not fasted prior to dosing. Animals were kept under controlled 
environmental conditions, where the temperature and humidity range settings were set to 
maintain 65–75°F and 20–70%, respectively. Animal rooms were set for at least 10 air 
exchanges per hour (h) and the room lighting cycle on a 12 h light/dark cycle. Each animal 
was randomized and given a unique study-specific identification number and identified by 
tail-marking. Rats were housed in shoebox cages with wire mesh bottoms. Their body 
weights were determined prior to dosing. Each animal received a single IV dose at a 
nominal dose of 10 mg/kg via a femoral vein cannula, which was based on pre-dose body 
weight. The doses administered were determined by weighing the syringes before and after 
administration. After dosing, all the rats were returned to their cages. Cage-side observations 
were performed three times post-dose on the day of dosing and at least daily for the 
remainder of the study, as appropriate, and any observations were recorded. One pigmented 
rat per time point was scheduled for euthanasia at 0.5, 1, 3, 6, 8 and 24 h, and 2, 3, 4, 5 and 7 
days post-dose. Animals scheduled for euthanasia were deeply anesthetized with isoflurane, 
euthanized and frozen by submersion in a hexane/dry ice bath. All carcasses were stored at 
approximately − 20 °C prior to preparation for whole-body autoradiography.
The frozen carcasses were embedded in a 2% carboxymethylcellulose matrix and mounted 
on a microtome stage (Leica CM3600 Cryomacrocut, Nussloch, Germany) maintained at 
approximately −20 °C. Three quality control standards (QC), which were 2% 
carboxymethylcellulose fortified with [14C]glucose at one concentration (0.057 μCi/g), were 
placed into the frozen blocks prior to sectioning, and were used for section thickness quality 
control as per QPS SOP #WBA-003. Sections approximately 40 μm thick were taken in the 
sagittal plane, and captured on adhesive tape (Scotch Tape No. 8210, 3M Ltd., St. Paul, 
MN). Appropriate sections selected at various levels of interest in the block were collected 
to encompass the following tissues, organs and biological fluids, where possible: adipose 
(brown and white), adrenal gland, bile (in duct), blood, brain (cerebrum, cerebellum, 
medulla), bone, bone marrow, cecum (and contents), epididymis, eye (uveal tract and lens), 
Harderian gland, heart, kidney (renal cortex and medulla), large intestine (and contents), 
liver, lung, lymph node, pancreas, pituitary gland, prostate gland, salivary gland, seminal 
vesicles, skeletal muscle, skin, stomach (gastric mucosa and contents), small intestine (and 
contents), spleen, spinal cord, testis, thymus, thyroid and urinary bladder (and contents).
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Sections were allowed to dry by sublimation in the cryomicrotome at − 20 °C for at least 48 
h after cutting. A set of sections were mounted on a cardboard backing, covered with a thin 
plastic wrap, and exposed along with calibration standards of 14C-blood (0.0008, 0.0009, 
0.0012, 0.0017, 0.0021, 0.0034, 0.0065, 0.0125, 0.0267, 0.0516, 0.1028, 0.2081, 0.7680, 
3.5737 and 8.1770 μCi/g) to 14C-sensitive phosphor imaging plates (Fuji Biomedical, 
Stamford, CT). The image plates and sections were placed in light-tight exposure cassettes 
for a 4-day exposure at room temperature. The image plates were scanned using the 
Typhoon 9410® image acquisition system (GE/Molecular Dynamics, Sunnyvale, CA) and 
the resultant images stored by a dedicated QPS computer server. Quantification was 
performed by image densitometry using MCID image analysis software (v. 6.0 or higher, 
GE/Imaging Research Inc., St. Catherines, Ontario, Canada) and a standard curve 
constructed from the integrated response (MDC/mm2) and the nominal concentrations of 
the 14C-blood standards. The concentrations of radioactivity were expressed as the μg 
equivalents of VNP40101M per gram sample (μg equiv/g).
Results and discussion
Mass balance
All animals appeared to be healthy at the start of the study and animals from Group 1 and 
Group 2 completed the study without incident. Group 3 rats (Rats 9, 10, 11 and 12) 
exhibited labored breathing and died within a few minutes after blood transfusion following 
the 7 h blood sample collection. After a complete investigation by the attending veterinarian, 
the cause of death was attributed to acute pulmonary distress precipitated by the infusion of 
particulates present in the donor blood. The deaths were not attributed to VNP40101M. A 
replacement cohort of Group 3 animals were dosed 1 week later (Rats 9A, 10A, 11A and 
12A) and no adverse events were noted during the course of the study.
As shown in Figure 2, most of the dose was excreted in the urine, with 51.4 ± 1.0% 
recovered within 168 h post-dose. The majority (46.7%) of this excretion occurred within 24 
h. Fecal excretion of the IV dose, 5.6 ±0.6%, suggests biliary excretion may be a minor 
route for the elimination of VNP40101M and metabolites. A significant portion of the dose 
(21.7 ±6.9%) was retained in the carcass 168 h post-dose. This may not be unexpected given 
the mechanism of action for the molecule. The mean total recovery of radioactivity in urine, 
feces, cage rinses, cage washes, cage wipes and carcass was 81.1 ±5.6%. The total recovery 
of volatile radioactivity was 11.0 ±1.2%, with 9.6% recovered within the first 24 h. When 
these results were added to the recovery of radioactivity from the Group 1 animals, an 
average of 92.1% of the administered dose was accounted for in the excreta and carcass.
Individual and mean plasma radioactivity concentrations for Group 3 rats are given in Table 
1 and are plotted in Figure 3. In Group 3 rats, the mean maximum plasma radioactivity 
concentration (8.352 ± 0.805 μg equivalents/mL) was observed at 0.083 h, the first sample 
collection time. Total radioactivity in plasma declined with a mean terminal half-life of 61.8 
±11.3 h, with a mean radioactivity of 1.408 ±0.115 μg equivalents/mL detected in plasma at 
48 h post-dose. These pharmacokinetic estimates, representing both parent and metabolites, 
must be interpreted cautiously because sampling was only carried out to 48 h post-dose.
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Quantitative whole-body autoradiography
There were no remarkable observations throughout the study for all the rats. Whole-body 
autoradiograms show the patterns of radioactivity distribution in tissues. Figure 4 is a 
representative QWBA profile of the radioactivity distribution in a male pigmented rat at 0.5 
h Post-dose following a single IV administration of [14C]VNP40101M at a target dose of 10 
mg/kg. The concentrations of drug-derived radioactivity in the tissues of rats following IV 
bolus administration of [14C]VNP40101M are summarized in Table 2. Forty-two areas 
representing highly and poorly perfused organs, important target organs like liver, lung and 
brain and excreta (urinary bladder contents, bile and cecal contents) were sampled. Drug-
derived radioactivity was widely distributed to tissues. Maximum concentrations were 
observed 0.5 or 1 h post-dose for most tissues (28 of 42). The highest concentrations of 
radioactivity were found in the small intestine contents at 0.5 h (112.137 μg equiv/g), and 
urinary bladder contents at 3 h (89.636 μg equiv/g), which probably reflect excretion of drug 
and metabolites. The highest concentrations in specific organs were found in the renal cortex 
at 1 h (28.582 μg equiv/g), small intestine at 3 h (16.946 μg equiv/g), Harderian gland at 3 h 
(12.332 μg equiv/g) and pancreas at 3 h (12.635 μg equiv/g). Concentrations in the 
cerebrum, cerebellum, medulla and spinal cord were maximal at 0.5 h post-dose and 
persisted for 7 days. The radioactivity was mostly eliminated over 7 days, which suggested 
the potential for distribution into tissues. The calculated half-lives for the elimination of total 
radioactivity from tissues ranged from 51 h for the Harderian gland to 262 h for white 
adipose tissue. These values must be interpreted cautiously because only one animal was 
sampled at each time point and the inter-animal variability is unknown. Tissue 
concentrations 7 days post-dose were generally up to 4-fold the LLOQ (0.108 μg equiv/g); 
some of them (19 of 42 samples) were BQL.
Human dosimetry predictions
The individual predicted human tissue exposures to radioactivity after a 100 μCi, IV dose of 
[14C]VNP40101M were summarized and can be found in Table 2. The predicted tissue 
exposure in humans given a single 100 μCi IV dose of [14C] VNP40101M is shown in Table 
3. The predicted exposure was less than 0.4% of the 3–5 rem limits specified by the Code of 
Federal Regulations (21 CFR: part 361.1, section b, 3i). Consistent with an IV dose, blood 
had the highest predicted radiation exposure (0.01308 rem). The maximum predicted whole 
body exposure to radioactivity from a 100 μCi, IV dose of [14C]VNP40101M to humans 
was estimated to be 0.0566 rem, which was approximately 1.9% of the 3 rem limit specified 
by the Code of Federal Regulations (21 CFR: part 361.1, section b, 3i). The cumulated 
exposure, estimated using the proposed human dose and longest tissue half-life for the rat, 
was 37728 μCi·h.
Metabolite/decomposition products of laromustine formed in vitro and in vivo
Table 4 shows the structures, molecular formula and the molecular weights of the 
metabolite/decomposition products of laromustine formed in HLM incubations and rat 
plasma in vivo. Detailed results from experiments with radioactive 14C-laromustine, cross-
species liver microsomes, in vitro mass balance and reaction phenotyping are reported 
elsewhere (Nassar et al., 2009).
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Conclusions
This study is the first QWBA to provide images of whole-body biodistribution of 
radiolabeled laromustine. Drug-derived radioactivity was widely distributed to tissues 
through 7 days post-dose after a single 10 mg/kg IV bolus dose of [14C]VNP40101M to 
male pigmented rats. Maximum concentrations were observed at 0.5 or 1 h post-dose for 
majority of tissues (28 of 42). The highest concentrations of radioactivity were found in the 
small intestine contents at 0.5 h (112.137 μg equiv/g), urinary bladder contents at 3h (89.636 
μg equiv/g) and probably reflect excretion of drug and metabolites. The highest 
concentrations in specific organs were found in the renal cortex at 1 h (28.582 μg equiv/g), 
small intestine at 3h (16.946 μg equiv/g), Harderian gland at 3h (12.332 μg equiv/g) and 
pancreas at 3h (12.635 μg equiv/g). Concentrations in the cerebrum, cerebellum, medulla 
and spinal cord were maximal at 0.5 h post-dose and persisted for 7 days. Selective 
distribution into, or retention by, melanin containing tissues was not apparent. The predicted 
total body and target organ exposures for humans given a single 100 μCi IV dose of 
[14C]VNP40101M were well within the medical guidelines for maximum radioactivity 
exposures in human subjects.
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Figure 1. 
Chemical structure of [14C]laromustine (VNP40101M).
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Figure 2. 
Mean cumulative recovery of radioactivity in urine and feces of Group 1 rats, expired air of 
Group 2 rats and carcasses of Group 1 rats following an intravenous bolus dose of 
[14C]VNP40101M at a target dose of 10 mg/kg.
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Figure 3. 
Individual plasma concentrations of total radioactivity versus time in Group 3 male rats 
following intravenous bolus target dose of 10 mg/kg.
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Figure 4. 
Whole-body autoradiogram of the radioactivity distribution in a male pigmented rat at 0.5 h 
post-dose (rat # 2) following a single IV administration of [14C]VNP40101M at a target 
dose of 10 mg/kg.
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Table 4
Metabolite/decomposition products of laromustine formed in HLM incubation and in vivo.
Components Molecular formula MW, amu In vitro In vivo
C3H8O3 124.2 Yes ND
C2H5ClO 80.5 Yes NT
C4H10N2O4S2 214.3 Yes Yes
C6H14C1N3O6S2 323.8 Yes Yes
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Components Molecular formula MW, amu In vitro In vivo
C4H11C1N2O4S2 250.7 Yes Yes
C6H14C1N3O5S2 307.8 Yes Yes
ND, not detected; NT, not tested.
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